Xiaobing Qin

735 total citations
30 papers, 613 citations indexed

About

Xiaobing Qin is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Xiaobing Qin has authored 30 papers receiving a total of 613 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 11 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Xiaobing Qin's work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), MicroRNA in disease regulation (6 papers) and RNA modifications and cancer (5 papers). Xiaobing Qin is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (6 papers), MicroRNA in disease regulation (6 papers) and RNA modifications and cancer (5 papers). Xiaobing Qin collaborates with scholars based in China and United States. Xiaobing Qin's co-authors include Shaorong Yu, Jifeng Feng, Bo Shen, Leilei Zhou, Meiqi Shi, Yong Hu, Xiaoyue Xu, Dali Yan, Siwen Liu and Jian Wu and has published in prestigious journals such as The Journal of Cell Biology, Oncogene and Oncotarget.

In The Last Decade

Xiaobing Qin

30 papers receiving 610 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaobing Qin China 12 448 355 127 77 42 30 613
Tae‐Su Han South Korea 14 520 1.2× 383 1.1× 110 0.9× 88 1.1× 38 0.9× 24 718
Jiaqi Yin China 8 389 0.9× 325 0.9× 82 0.6× 88 1.1× 46 1.1× 20 525
Guo-Sheng Hu China 14 613 1.4× 345 1.0× 124 1.0× 72 0.9× 71 1.7× 38 824
Meisongzhu Yang China 12 386 0.9× 220 0.6× 104 0.8× 114 1.5× 63 1.5× 16 524
Lu Xu China 15 463 1.0× 363 1.0× 97 0.8× 69 0.9× 47 1.1× 37 592
Songming Ding China 12 335 0.7× 231 0.7× 127 1.0× 72 0.9× 29 0.7× 20 510
Mengxi Huang China 15 428 1.0× 195 0.5× 169 1.3× 90 1.2× 45 1.1× 31 655
Simon Haefliger Switzerland 12 342 0.8× 204 0.6× 73 0.6× 51 0.7× 49 1.2× 33 604
Xiangdong Hua China 11 544 1.2× 397 1.1× 95 0.7× 70 0.9× 43 1.0× 20 764
Jean-Philippe Cosse Belgium 8 316 0.7× 313 0.9× 158 1.2× 92 1.2× 80 1.9× 9 611

Countries citing papers authored by Xiaobing Qin

Since Specialization
Citations

This map shows the geographic impact of Xiaobing Qin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaobing Qin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaobing Qin more than expected).

Fields of papers citing papers by Xiaobing Qin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaobing Qin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaobing Qin. The network helps show where Xiaobing Qin may publish in the future.

Co-authorship network of co-authors of Xiaobing Qin

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaobing Qin. A scholar is included among the top collaborators of Xiaobing Qin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaobing Qin. Xiaobing Qin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Qu, Pengfei, Xiao Ma, Luyao Ma, et al.. (2024). Progress in the treatment of advanced hepatocellular carcinoma with immune combination therapy. World Journal of Gastrointestinal Oncology. 16(2). 273–286. 8 indexed citations
2.
Wang, Hongmei, et al.. (2024). Clinicopathological features, psychological status, and prognosis of 33 patients with occult breast cancer. World Journal of Psychiatry. 14(1). 76–87. 2 indexed citations
3.
Wang, Hongmei, Yuqi Li, Xiaobing Qin, et al.. (2024). Efficacy and safety of gemcitabine/nab-paclitaxel combined with anlotinib and PD-1 inhibitors as a first-line treatment for advanced pancreatic cancer. International Immunopharmacology. 139. 112635–112635. 4 indexed citations
4.
Yao, Zhiyuan, Xiaoxiao Chen, Yuqi Li, et al.. (2024). Impact of baseline hepatitis B virus viral load on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy. World Journal of Gastrointestinal Oncology. 16(6). 2504–2519. 2 indexed citations
5.
6.
Qu, Pengfei, et al.. (2023). Safety and Efficacy of TACE + Lenvatinib in Treating Advanced Hepatocellular Carcinoma: A Systematic Review and Meta- analysis. Journal of Gastrointestinal and Liver Diseases. 32(2). 222–229. 3 indexed citations
7.
Qin, Xiaobing, Zhiyuan Xu, Meng Wu, et al.. (2022). Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China. Frontiers in Genetics. 13. 1000448–1000448. 8 indexed citations
8.
Qin, Xiaobing, et al.. (2022). Comparison of Hepatic Arterial Infusion Chemotherapy and Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Journal of Gastrointestinal and Liver Diseases. 31(3). 336–343. 4 indexed citations
9.
10.
Di, Jiehui, Hui Wang, Zhongjun Zhao, et al.. (2021). CPEB4 Inhibit Cell Proliferation via Upregulating p21 mRNA Stability in Renal Cell Carcinoma. Frontiers in Cell and Developmental Biology. 9. 687253–687253. 5 indexed citations
11.
Yu, Shaorong, Huanhuan Sha, Xiaobing Qin, et al.. (2020). EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells. Oncogene. 39(13). 2643–2657. 55 indexed citations
12.
13.
Wang, Qingbo, Bo Shen, Xiaobing Qin, Siwen Liu, & Jifeng Feng. (2019). Akt/mTOR and AMPK signaling pathways are responsible for liver X receptor agonist GW3965-enhanced gefitinib sensitivity in non-small cell lung cancer cell lines. Translational Cancer Research. 8(1). 66–76. 14 indexed citations
14.
Jing, Changwen, Haixia Cao, Xiaobing Qin, et al.. (2018). Exosome‑mediated gefitinib resistance in lung cancer HCC827 cells via delivery of miR‑21. Oncology Letters. 15(6). 9811–9817. 53 indexed citations
15.
Yu, Shaorong, Wenbo Sun, Xiaobing Qin, et al.. (2017). MiRNA signature predicts the response of patients with advanced lung adenocarcinoma to platinum-based treatment. Journal of Cancer Research and Clinical Oncology. 144(3). 431–438. 10 indexed citations
16.
Yu, Shaorong, et al.. (2017). MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer. Anti-Cancer Drugs. 28(8). 852–860. 41 indexed citations
17.
18.
Qin, Xiaobing, Shaorong Yu, Leilei Zhou, et al.. (2017). Cisplatin-resistant lung cancer cell–derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100–5p-dependent manner. International Journal of Nanomedicine. Volume 12. 3721–3733. 209 indexed citations
19.
20.
Hu, Yong, Xiaobing Qin, Haixia Cao, Shaorong Yu, & Jifeng Feng. (2016). Reversal effects of local anesthetics on P-glycoprotein-mediated cancer multidrug resistance. Anti-Cancer Drugs. 28(3). 243–249. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tae‐Su Han Breakdown of academic impact, for papers by Jiaqi Yin Breakdown of academic impact, for papers by Guo-Sheng Hu Breakdown of academic impact, for papers by Meisongzhu Yang Breakdown of academic impact, for papers by Lu Xu Breakdown of academic impact, for papers by Songming Ding Breakdown of academic impact, for papers by Mengxi Huang Breakdown of academic impact, for papers by Simon Haefliger Breakdown of academic impact, for papers by Xiangdong Hua Breakdown of academic impact, for papers by Jean-Philippe Cosse
Rankless by CCL
2026